GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (LTS:0KF3) » Definitions » Cyclically Adjusted PS Ratio

Palatin Technologies (LTS:0KF3) Cyclically Adjusted PS Ratio : (As of Jun. 08, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Palatin Technologies Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Palatin Technologies Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Palatin Technologies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies Cyclically Adjusted PS Ratio Chart

Palatin Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.47 - 3.35 1.41 0.44

Palatin Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.44 0.32 0.89 -

Competitive Comparison of Palatin Technologies's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Palatin Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palatin Technologies's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palatin Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Palatin Technologies's Cyclically Adjusted PS Ratio falls into.



Palatin Technologies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Palatin Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Palatin Technologies's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Palatin Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 1.142 100.428 1.498
201412 1.825 99.070 2.427
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 1.377 102.862 1.764
201706 4.306 103.349 5.490
201709 3.345 104.136 4.233
201712 1.309 104.011 1.658
201803 1.135 105.290 1.421
201806 2.344 106.317 2.905
201809 0.004 106.507 0.005
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 6.025 108.070 7.347
201909 0.010 108.329 0.012
201912 0.002 108.420 0.002
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 -0.031 109.815 -0.037
202012 -0.017 109.897 -0.020
202103 0.009 111.754 0.011
202106 0.018 114.631 0.021
202109 0.017 115.734 0.019
202112 0.034 117.630 0.038
202203 0.023 121.301 0.025
202206 0.081 125.017 0.085
202209 0.090 125.227 0.095
202212 0.095 125.222 0.100
202303 0.105 127.348 0.109
202306 0.150 128.729 0.154
202309 0.173 129.860 0.176
202312 0.144 129.419 0.147
202403 0.000 131.776 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Palatin Technologies  (LTS:0KF3) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Palatin Technologies Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Palatin Technologies (LTS:0KF3) Business Description

Traded in Other Exchanges
Address
4B Cedar Brook Drive, Cranbury, NJ, USA, 08512
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Palatin Technologies (LTS:0KF3) Headlines

No Headlines